25,00 €
Deine Einschätzung
Agios Pharmaceuticals Inc. Aktie
Was spricht für und gegen Agios Pharmaceuticals Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Agios Pharmaceuticals Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | 2,46 % | 5,93 % | 9,65 % | -22,84 % | 7,76 % | -3,85 % | -40,02 % |
| Iovance Biotherapeutics Inc. | 1,22 % | 12,89 % | 17,33 % | -54,21 % | 3,20 % | -64,99 % | -93,71 % |
| United Therapeutics | -0,27 % | 1,90 % | 2,33 % | 16,88 % | -4,38 % | 70,96 % | 181,79 % |
| Neurocrine Bioscience | -1,90 % | 4,40 % | -4,92 % | -1,27 % | -10,57 % | 12,93 % | 16,69 % |
Kommentare
News
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
On February 17, 2026, Rock Springs Capital Management LP disclosed in an SEC filing that it sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth quarter, an estimated $5.59
Here's Why Shares in Agios Pharmaceuticals Popped Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME
Why Shares in Agios Pharmaceuticals Got Crushed Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle



